RGNX stock forecast
Our latest prediction for REGENXBIO, Inc.'s stock price was made on the Feb. 5, 2020 when the stock price was at 49.26$.
In the short term (2weeks), RGNX's stock price should underperform the market by -1.96%. During that period the price should oscillate between -7.45% and +6.04%.
In the medium term (3months), RGNX's stock price should underperform the market by -7.16%. During that period the price should oscillate between -27.01% and +15.21%.Get email alerts
About REGENXBIO, Inc.
REGENXBIO, Inc. is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.
At the moment the company generates 64M USD in revenues.
On its last earning announcement, the company reported a loss of -1.81$ per share.
The book value per share is 9.82$
Three months stock forecastFeb. 5, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|